These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39340288)

  • 41. [TMEM64 is highly expressed in hepatocellular carcinoma and promotes tumor cell proliferation and invasion].
    Cao D; Cai J; Li Y; Dong R; Wang Z; Zuo X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Aug; 43(8):1345-1355. PubMed ID: 37712271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Over-expression of SRD5A3 and its prognostic significance in breast cancer.
    Zhang YP; Na WT; Dai XQ; Li RF; Wang JX; Gao T; Zhang WB; Xiang C
    World J Surg Oncol; 2021 Aug; 19(1):260. PubMed ID: 34465365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma.
    Qiu MJ; Zhang L; Chen YB; Zhu LS; Zhang B; Li QT; Yang SL; Xiong ZF
    Int J Biochem Cell Biol; 2021 Aug; 137():106037. PubMed ID: 34217812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
    Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
    J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma.
    Chang Q; Xu Y; Wang J; Jing H; Rao L; Tang W; Zhang Z; Wu X
    Comput Math Methods Med; 2021; 2021():8556888. PubMed ID: 34819993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma.
    Huang R; Chen Z; Li W; Fan C; Liu J
    Int J Oncol; 2020 May; 56(5):1199-1211. PubMed ID: 32319580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.
    Qi W; Bai Y; Wang Y; Liu L; Zhang Y; Yu Y; Chen H
    APMIS; 2022 Jul; 130(7):371-382. PubMed ID: 35255180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Type-1 Na
    Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY
    Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
    Yang Y; Zhao W; Du J; Wang Y
    Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F; Cai D
    Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma.
    Shi J; Wen K; Mui S; Li H; Liao H; He C; Yan Y; Zhou Z; Xiao Z
    Clin Transl Oncol; 2024 Sep; 26(9):2181-2197. PubMed ID: 38472558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A m
    Xu S; Zhang Y; Yang Y; Dong K; Zhang H; Luo C; Liu SM
    Front Immunol; 2024; 15():1374465. PubMed ID: 39119345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
    Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
    Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma.
    Zuo A; Lv J; Jia W; Ba Y; Liu S; Zhang Y; Weng S; Xu H; Liu L; Wang L; Han X; Liu Z
    BMC Cancer; 2024 Sep; 24(1):1152. PubMed ID: 39289669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.
    Pan B; Cheng J; Tan W; Wu X; Fan Q; Fan L; Jiang M; Yu R; Cheng X; Deng Y
    Aging (Albany NY); 2024 May; 16(9):8171-8197. PubMed ID: 38738999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of mitochondrial phosphoenolpyruvate carboxykinase with prognosis and immune regulation in hepatocellular carcinoma.
    Li C; Zhang ED; Ye Y; Xiao Z; Huang H; Zeng Z
    Sci Rep; 2024 Jun; 14(1):14051. PubMed ID: 38890507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
    Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
    Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prognostic Significance of
    Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.